Surendra Haribhau Bodakhe
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Surendra Haribhau Bodakhe has a total of 61 co-authors. Here are the top co-authors by number of shared publications:
- Rajesh Choudhary
Department of Pharmacology, Shri Shankaracharya College of Pharmaceutical Sciences, Shri Shankaracharya Professional University, Bhilai, India
14 shared publications Ashmita Das
Department of Pharmacy, Guru Ghasidas Vishwavidyalaya (A Central University), Bilaspur, Chhattisgarh, India
13 shared publicationsDurlav Chowdhury
12 shared publicationsAmrita Singh
National Institute of Pharmaceutical Education and Research, Ahmedabad, India
11 shared publicationsJaya Shree
7 shared publicationsNidhi Kumari
6 shared publications
Latest Publications
- Open Access
- 1 November 2026
- Published by KEAI Publishing in NeuroMarkers
Multidimensional biomarkers for systemic diseases: A narrative review on the implications of growth differentiation factor 15 for neurological health and beyond
- 1 November 2026
- Published by KEAI Publishing in NeuroMarkers
Open AccessMultidimensional biomarkers for systemic diseases: A narrative review on the implications of growth differentiation factor 15 for neurological health and beyond
- 23 September 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 95
Targeting pulmonary and arterial chemoreceptors via inhaled therapeutics: A novel pathway to blunt hypoxia-induced pulmonary hypertension?
- 23 September 2026
- Published by Elsevier in Pulmonary Pharmacology & Therapeutics
- Vol. 95
Targeting pulmonary and arterial chemoreceptors via inhaled therapeutics: A novel pathway to blunt hypoxia-induced pulmonary hypertension?
- 3 September 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1034
Precision genome editing strategies for enduring lipid lowering in atherosclerosis
- 3 September 2026
- Published by Elsevier in European Journal of Pharmacology
- Vol. 1034
Precision genome editing strategies for enduring lipid lowering in atherosclerosis
- 19 June 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28  (1)
Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications
Head and neck squamous cell carcinoma (HNSCC) is a global malignancy characterised by extremely low survival rates, primarily contributed to by late diagnosis, tumour heterogeneity, and resistance to available therapies. Deciphering reliable biomarkers is crucial for early diagnosis, prognosis and personalized therapy. This review discusses the possibilities of clusterin (CLU) as an emerging biomarker in the field of HNSCC therapeutics by incorporating insights derived from preclinical, clinical and proteomic data. The expression of CLU in HNSCC cases has been found to be correlated with advanced stages of the tumour, metastatic potential higher histological grades and therapeutic resistance. Mechanistic studies demonstrate that CLU plays a dual role in enhancing tumour cell survival and facilitating apoptosis, contingent upon isoform and environmental context. Recent findings confirm the effectiveness of CLU as a biomarker for early diagnosis, risk evaluation, and forecasting therapeutic response. This review also focuses on the comparison of CLU to known HNSCC biomarkers and stresses the progress made in non-invasive screening and targeted therapies. In conclusion, CLU shows strong potential as a biomarker and therapeutic target, warranting further research for clinical application in HNSCC.
- 19 June 2026
- Published by Springer Nature in Current Oncology Reports
- Vol. 28  (1)
Clusterin in Head and Neck Squamous Cell Carcinoma: Diagnostic, Prognostic, and Therapeutic Implications
Head and neck squamous cell carcinoma (HNSCC) is a global malignancy characterised by extremely low survival rates, primarily contributed to by late diagnosis, tumour heterogeneity, and resistance to available therapies. Deciphering reliable biomarkers is crucial for early diagnosis, prognosis and personalized therapy. This review discusses the possibilities of clusterin (CLU) as an emerging biomarker in the field of HNSCC therapeutics by incorporating insights derived from preclinical, clinical and proteomic data. The expression of CLU in HNSCC cases has been found to be correlated with advanced stages of the tumour, metastatic potential higher histological grades and therapeutic resistance. Mechanistic studies demonstrate that CLU plays a dual role in enhancing tumour cell survival and facilitating apoptosis, contingent upon isoform and environmental context. Recent findings confirm the effectiveness of CLU as a biomarker for early diagnosis, risk evaluation, and forecasting therapeutic response. This review also focuses on the comparison of CLU to known HNSCC biomarkers and stresses the progress made in non-invasive screening and targeted therapies. In conclusion, CLU shows strong potential as a biomarker and therapeutic target, warranting further research for clinical application in HNSCC.
- 1 June 2026
- Published by Elsevier in Next Research
- Vol. 11
Therapeutic implications of targeting lipid metabolism and mitochondrial function: A review
- 1 June 2026
- Published by Elsevier in Next Research
- Vol. 11
Therapeutic implications of targeting lipid metabolism and mitochondrial function: A review
- 25 May 2026
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-17
Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous malignancies frequently resistant to standard therapies. Immunotherapy represents a novel management frontier. This review synthesises clinical and translational evidence regarding immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and oncolytic virotherapy in GEP-NENs. We examine critical antigenic targets (somatostatin receptors, DLL3) and strategies to overcome the immunosuppressive tumour immune microenvironment (TIME). While single-agent ICIs show modest efficacy in well-differentiated NETs, dual checkpoint blockade exhibits durable disease control in poorly differentiated NECs. Targeted modalities like DLL3-directed bispecific antibodies demonstrate significant early efficacy. Furthermore, we summarise highly synergistic combinatorial approaches, specifically integrating immunotherapy with anti-angiogenic agents and peptide receptor radionuclide therapy (PRRT). Ongoing biomarker-driven trials and molecular profiling remain essential to optimise patient selection and treatment sequencing.
- 25 May 2026
- Published by Taylor & Francis in Journal of Chemotherapy
- p. 1-17
Immunotherapeutic strategies in gastroenteropancreatic neuroendocrine neoplasms: present condition and future developments
Gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs) are heterogeneous malignancies frequently resistant to standard therapies. Immunotherapy represents a novel management frontier. This review synthesises clinical and translational evidence regarding immune checkpoint inhibitors (ICIs), bispecific T-cell engagers, chimeric antigen receptor (CAR) T-cell therapies, and oncolytic virotherapy in GEP-NENs. We examine critical antigenic targets (somatostatin receptors, DLL3) and strategies to overcome the immunosuppressive tumour immune microenvironment (TIME). While single-agent ICIs show modest efficacy in well-differentiated NETs, dual checkpoint blockade exhibits durable disease control in poorly differentiated NECs. Targeted modalities like DLL3-directed bispecific antibodies demonstrate significant early efficacy. Furthermore, we summarise highly synergistic combinatorial approaches, specifically integrating immunotherapy with anti-angiogenic agents and peptide receptor radionuclide therapy (PRRT). Ongoing biomarker-driven trials and molecular profiling remain essential to optimise patient selection and treatment sequencing.
- 22 April 2026
- Published by Elsevier in Obesity Medicine
- Vol. 61
Exploring novel therapeutic approaches for managing cardiovascular-kidney-metabolic syndrome: A review of pharmacological advancements
- 22 April 2026
- Published by Elsevier in Obesity Medicine
- Vol. 61
Exploring novel therapeutic approaches for managing cardiovascular-kidney-metabolic syndrome: A review of pharmacological advancements
- 17 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126882
Nebulisation: an effective approach for delivering drugs to the heart
- 17 April 2026
- Published by Elsevier in International Journal of Pharmaceutics
- Vol. 697, 126882
Nebulisation: an effective approach for delivering drugs to the heart
- 25 February 2026
- Published by Elsevier in Next Research
- Vol. 8
Investigating emerging biomarkers for evaluating cardiac insufficiency
- 25 February 2026
- Published by Elsevier in Next Research
- Vol. 8
Investigating emerging biomarkers for evaluating cardiac insufficiency